The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A Phase I trial of ELA026, a SIRP inhibitor, in treatment-naïve HLH
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a Phase I study of ELA026, a signal regulatory protein (SIRP) inhibitor, in treatment-naïve malignancy-associated hemophagocytic lymphohistiocytosis (HLH). Dr Iyer highlights that ELA026 improved outcomes for these patients, paving the way for a Phase II expansion study that aims to enroll patients with most lymphomas. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
ELA026 is a pan SIRP inhibitor. It’s a first-in-class monoclonal antibody that works on the SIRP target. We’re all familiar with SIRP alpha. There’s also the SIRP beta, SIRP gamma, which is highly present in macrophages and some activated T-cells. And we know that macrophages and T-cell dysfunction are the cause for hemophagocytic lymphohistiocytosis. It’s a deadly disease...
ELA026 is a pan SIRP inhibitor. It’s a first-in-class monoclonal antibody that works on the SIRP target. We’re all familiar with SIRP alpha. There’s also the SIRP beta, SIRP gamma, which is highly present in macrophages and some activated T-cells. And we know that macrophages and T-cell dysfunction are the cause for hemophagocytic lymphohistiocytosis. It’s a deadly disease. The mortality with or without treatment is about 50 to 70 percent within the first two months. And so this study started as a first in human as a Phase I and we dose escalated, went to a Phase Ib where we treated several patients and majority of these patients were T-cell lymphoma patients. Unfortunately a lot of T-cell lymphoma patients developed this hemophagocytosis so it’s called as lymphoma-associated HLH and in reality these patients don’t do well even with chemotherapy so they need something additional and when this protocol was able to combine the antibody ELA026 with chemotherapy and we saw several responses that allowed patients. So if you look at the benchmark of 60 days where the mortality is about a hundred percent this is able to save patients or at least have no mortality for up to 60 day. And also saw some interesting data of reduction in the burden of the T-cell lymphoma at the same time. So it’s first in class, I think it’s going to Phase II expansion, a pivotal study that hopefully will enroll most lymphomas.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Innate: Research Funding; Secura Bio: Membership on an entity’s Board of Directors or advisory committees; Acrotech: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Crispr: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Salarius: Consultancy; Ono: Research Funding; IMPaRT.AI: Other: Stock, Founder; Trillium: Research Funding; Astra Zeneca: Research Funding; Merck: Research Funding; Yingli: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Legend: Research Funding; Seagen/Pfizer: Membership on an entity’s Board of Directors or advisory committees, Research Funding; JCO-CCI: Other: Editor.
